Opaleye Management Inc. - 29 Apr 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Role: 10%+ Owner
Signature: Opaleye Management Inc., By: /s/ James Silverman, President
Issuer symbol: N/A
Transactions as of: 29 Apr 2022
Net transactions value: +$14,058
Form type: 4
Filing time: 29 Apr 2022, 18:27:26 UTC
Previous filing: 25 Apr 2022
Next filing: 10 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCON	Common Stock, par value $0.001 per share	Purchase	$12,078	+6,100	+0.21%	$1.98	2,926,100	22 Apr 2022	By Opaleye, L.P.	F1, F3
transaction	TCON	Common Stock, par value $0.001 per share	Purchase	$1,980	+1,000	+0.3%	$1.98	336,114	22 Apr 2022	By Managed Account	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TCON	Prefunded Warrants						1,889,513	29 Apr 2022	Common Stock	1,889,513	$0.0100	By Opaleye,L.P.	F1, F4
holding	TCON	Prefunded Warrants						1,358,593	29 Apr 2022	Common Stock	1,358,593	$0.0100	By Opaleye,L.P.	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2	Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F3	The common stock was purchased by the reporting person in open market transactions on the transaction date, with a purchase price of $1.98. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased.
F4	The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 9.99% of the issuers then outstanding shares.